uniQure (NASDAQ:QURE) Given New $35.00 Price Target at Chardan Capital

uniQure (NASDAQ:QURE) had its price objective reduced by Chardan Capital from $38.00 to $35.00 in a report issued on Tuesday morning,Benzinga reports. Chardan Capital currently has a buy rating on the biotechnology company’s stock.

A number of other equities analysts also recently commented on QURE. HC Wainwright restated a “buy” rating and issued a $70.00 target price on shares of uniQure in a research note on Thursday, May 29th. Guggenheim reaffirmed a “buy” rating and set a $28.00 price target on shares of uniQure in a report on Monday, May 12th. Cantor Fitzgerald raised uniQure to a “strong-buy” rating in a report on Monday, May 19th. Finally, Wall Street Zen cut uniQure from a “hold” rating to a “sell” rating in a report on Saturday, June 14th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $37.55.

uniQure Stock Down 8.7%

NASDAQ:QURE opened at $13.68 on Tuesday. The company has a debt-to-equity ratio of 1.53, a quick ratio of 11.99 and a current ratio of 11.99. The stock has a 50-day simple moving average of $14.91 and a 200 day simple moving average of $13.68. uniQure has a one year low of $4.45 and a one year high of $19.18. The company has a market capitalization of $749.39 million, a price-to-earnings ratio of -3.12 and a beta of 0.08.

uniQure (NASDAQ:QURE) last issued its earnings results on Friday, May 9th. The biotechnology company reported ($0.82) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.25. uniQure had a negative return on equity of 483.87% and a negative net margin of 1,077.05%. The company had revenue of $1.57 million during the quarter, compared to the consensus estimate of $5.93 million. Sell-side analysts predict that uniQure will post -3.75 EPS for the current fiscal year.

Insider Buying and Selling

In other uniQure news, insider Jeannette Potts sold 4,670 shares of the company’s stock in a transaction on Monday, June 16th. The stock was sold at an average price of $15.14, for a total value of $70,703.80. Following the transaction, the insider owned 115,073 shares of the company’s stock, valued at approximately $1,742,205.22. This represents a 3.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David D. Meek sold 2,112 shares of the company’s stock in a transaction on Friday, June 20th. The shares were sold at an average price of $14.45, for a total value of $30,518.40. Following the completion of the transaction, the director directly owned 34,190 shares in the company, valued at $494,045.50. This represents a 5.82% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 22,144 shares of company stock valued at $322,426 in the last three months. Insiders own 4.79% of the company’s stock.

Institutional Trading of uniQure

Hedge funds and other institutional investors have recently modified their holdings of the business. Mraz Amerine & Associates Inc. acquired a new stake in shares of uniQure in the first quarter worth $106,000. KLP Kapitalforvaltning AS purchased a new stake in shares of uniQure during the second quarter worth $117,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of uniQure during the first quarter worth $152,000. ADAR1 Capital Management LLC purchased a new stake in shares of uniQure during the fourth quarter worth $177,000. Finally, Wells Fargo & Company MN raised its holdings in shares of uniQure by 13.9% during the fourth quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company’s stock worth $217,000 after acquiring an additional 1,503 shares in the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.